Compare Gilead Sciences, Inc. (GILD) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Open Text Corporation — how do they compare? Gilead Sciences, Inc. trades at $151.24 (market cap $182.40B), while Open Text Corporation trades at $23.63 (market cap $5.61B). The key difference: Gilead Sciences, Inc. is far larger — about 32.5× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.82%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Open Text Corporation for 23 Days on average.
| GILD | OTEX | |
|---|---|---|
Market Cap | $182.40B | $5.61B |
Volume | 4,469,821 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $155.80 | $39.69 |
52-Week Low | $116.74 | $20.01 |
Typical Hold Time | 111 Days | 23 Days |
Enterprise Value | $205.46B | $10.63B |
Dividend Yield | 2.23% | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
OTEX trades at $23.52, up 1.64% today, with a bearish technical signal despite recent earnings beats. The stock is attractively valued with a P/E of 9.01 and P/S of 1.1, supported by strong profitability margins. Recent news highlights debt restructuring and a strategic AI partnership with Cohere, while cash flow trends show operational strength but negative net cash flow.
The outlook is mixed: valuation discounts and cloud growth present opportunity, but high debt and bearish technicals pose risks. Analyst consensus is a Buy with a $28.30 target, implying potential upside, though execution on AI initiatives and debt management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
